N-Myc Downstream-Regulated Gene 4 ( NDRG4 ): A Candidate Tumor Suppressor Gene and Potential Biomarker for Colorectal Cancer

Melotte, Veerle; Lentjes, Marjolein H.F.M.; Bosch, Sandra M. van den; Hellebrekers, Debby M.E.I.; Hoon, Joep P.J. de; Wouters, Kristien; Daenen, Kathleen L.J.; Partouns-Hendriks, Iris; Stessels, Filip; Louwagie, Joost; Smits, Kim M.; Weijenberg, Matty P.; Sanduleanu, Silvia; Bakker, Carolina A.J. Khalid-de; Oort, Frank A.; Meijer, Gerrit A.; Jonkers, Daisy; Herman, James G.; Bruïne, Adriaan P. de; Engeland, Manon van

doi:10.1093/jnci/djp131

Cited by 183 publications

(177 citation statements)

References 42 publications

(13 reference statements)

Supporting

Mentioning

163

Contrasting

Unclassified

Order By: Relevance

“…In the present study, methylated markers BMP3, NDRG4, VIM, TFPI2, and their combination detected most colorectal cancers and adenomas Ͼ1 cm at high diagnostic specificity when assayed with QuARTS, which is consistent with previous reports by us and others (6,7,(13)(14)(15). Each of these markers can be considered for further evaluation in screening or diagnostic applications for colorectal neoplasms because of their broad coverage and early onset in the tumorigenesis of colorectal cancer.…”

Section: Methods For Detecting Methylated Markerssupporting

confidence: 92%

Quantification of Methylated Markers with a Multiplex Methylation-Specific Technology

et al. 2012

View full text Add to dashboard Cite

show abstract

Section: Methods For Detecting Methylated Markerssupporting

confidence: 92%

Quantification of Methylated Markers with a Multiplex Methylation-Specific Technology

et al. 2012

View full text Add to dashboard Cite

show abstract

“…These hypermethylation markers are promising tools to detect cancer cells in tissue and body fluids (6,7) with the use of simple PCR technology (8)(9)(10). Proof of principle for the clinical value of methylation markers has been reported for early detection and classification of cancer (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21), risk assessment and prognosis (19,(22)(23)(24), and prediction of therapy response (25)(26)(27), with some already having shown their importance in (pre)clinical practice. Thus, the promise of methylation changes to become a powerful diagnostic and predictive tool (6) is becoming a reality.…”

Section: Introductionmentioning

confidence: 99%

Analysis of Promoter CpG Island Hypermethylation in Cancer: Location, Location, Location!

Vlodrop

Niessen

Derks

et al. 2011

Clinical Cancer Research

Self Cite

122

102

View full text Add to dashboard Cite

The genetic and epigenetic alterations that underlie cancer pathogenesis are rapidly being identified. This provides novel insights in tumor biology as well as in potential cancer biomarkers. The somatic mutations in cancer genes that have been implemented in clinical practice are well defined and very specific. For epigenetic alterations, and more specifically aberrant methylation of promoter CpG islands, evidence is emerging that these markers could be used for the early detection of cancer as well as prediction of prognosis and response to therapy. However, the exact location of biologically and clinically relevant hypermethylation has not been identified for the majority of methylation markers. The most widely used approaches to analyze DNA methylation are based on primer-and probe-based assays that provide information for a limited number of CpG dinucleotides and thus for only part of the information available in a given CpG island. Validation of the current data and implementation of hypermethylation markers in clinical practice require a more comprehensive and critical evaluation of DNA methylation and limitations of the techniques currently used in methylation marker research. Here, we discuss the emerging evidence on the importance of the location of CpG dinucleotide hypermethylation in relation to gene expression and associations with clinicopathologic characteristics in cancer. Clin Cancer Res; 17(13); 4225-31. Ó2011 AACR.

show abstract

“…Reduced Ndrg2 expression has been observed in different cancers (Hu et al, 2004), and the tumor suppressive role of Ndrg2 and the status of Ndrg2 as a potential biomarker in cancer have been identified. Similarly, Ndrg4 is also regarded as a tumor suppressor gene (Melotte et al, 2009). In contrast, Ndrg3 is considered as a tumor…”

mentioning

confidence: 99%

Developmental expression of the N-myc downstream regulated gene (Ndrg) family during Xenopus tropicalis embryogenesis

Zhong

Zhou²,

Yang³

et al. 2015

Int. J. Dev. Biol.

View full text Add to dashboard Cite

The N-myc downstream regulated gene (Ndrg) family consists of four main members Ndrg1, 2, 3, and 4. The Ndrg genes are involved in many vital biological events including development. However, comprehensive expression patterns of this gene family during vertebrate embryogenesis remain largely unknown. Here, we analyzed the Ndrg family from the evolutionary perspective and examined the expression patterns of the Ndrg genes during Xenopus tropicalis embryogenesis. Different Ndrg family members of vertebrates are separated into different homology clusters which can be further classified into two groups and each Ndrg family member is well conserved during evolution. The temporal and spatial expression patterns of Ndrg1, 2, 3 and 4 are different during early Xenopus tropicalis development. Ndrg1, 2 and 4 are maternally expressed genes while Ndrg3 is a zygotically expressed gene. The Ndrg genes are differentially expressed in the developing central nervous system, the developing sensory organs, and the developing excretory organs. Moreover, they also show other specific expression domains. Our results indicate that the Ndrg genes exhibit specific expression patterns and may play different roles during vertebrate embryogenesis.

show abstract

N-Myc Downstream-Regulated Gene 4 ( NDRG4 ): A Candidate Tumor Suppressor Gene and Potential Biomarker for Colorectal Cancer

Abstract: NDRG4 is a candidate tumor suppressor gene in colorectal cancer whose expression is frequently inactivated by promoter methylation. NDRG4 promoter methylation is a potential biomarker for the noninvasive detection of colorectal cancer in stool samples.

Cited by 183 publications

References 42 publications

Quantification of Methylated Markers with a Multiplex Methylation-Specific Technology

Quantification of Methylated Markers with a Multiplex Methylation-Specific Technology

Analysis of Promoter CpG Island Hypermethylation in Cancer: Location, Location, Location!

Developmental expression of the N-myc downstream regulated gene (Ndrg) family during Xenopus tropicalis embryogenesis

Contact Info

Product

Resources

About